Examines molecular testing determinants for advanced non-small cell lung cancer in rural populations, highlighting crucial care access issues.
Key Points
This study aims to identify the factors affecting molecular testing for advanced non-small cell lung cancer (NSCLC) in rural settings of the United States.
Analyzed data from the SEER-Medicare database for patients diagnosed with advanced NSCLC (2014-2019)
Evaluated molecular testing rates, specifically focusing on EGFR testing using claims data
Surveyed multidisciplinary healthcare providers to identify barriers and facilitators to testing
Identified 8713 individuals with advanced NSCLC in rural areas
Only 21.1% underwent EGFR testing
Younger individuals and those with fewer comorbidities were more likely to receive testing
Higher rates of concurrent Medicaid coverage appeared as a barrier to testing